LabPulse

LabPulse.com serves as a complete online platform for professionals in the clinical laboratory sector. It offers a space for pathologists, lab technicians, business leaders, researchers, members of medical organizations, and industry representatives to connect and share knowledge on various topics related to the clinical lab field, all facilitated by the convenience of the internet. LabPulse keeps you updated with the most recent news and insights from the clinical lab community. Our team comprises experienced executives, editors, and software engineers who have a strong background in healthcare publishing.

Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#2078572

United States

#608220

Health/Health

#9817

Traffic sources

Monthly visitors

Articles

Helix launches genomic dataset of GLP-1 agonist-treated patients

2 months ago | labpulse.com | Liz Carey

Genetic testing and population genomics firm Helix announced the launch of a research-ready clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists. The GLP-1 Virtual Registry was built as part of the Helix Research Network (HRN). The registry is the latest of many therapeutic area-specific datasets within the HRN, which include cardiometabolic diseases, autoimmune conditions, neurodegenerative diseases, and others, Helix noted in a statement.
AstraDx receives $30M CARB-X funding for neonatal sepsis test

2 months ago | labpulse.com | Matt Limb |Nick Paul Taylor

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded $3 million to diagnostics company AstraDx to develop a rapid test for neonatal sepsis. In a statement, CARB-X said that AstraDx will use the funds to demonstrate feasibility of its diagnostic ahead of development; the firm aims to develop “a robust, low-cost instrument” to detect neonatal sepsis.
AstraDx receives $3M CARB-X funding for neonatal sepsis test

2 months ago | labpulse.com | Matt Limb |Nick Paul Taylor

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded $3 million to diagnostics company AstraDx to develop a rapid test for neonatal sepsis. In a statement, CARB-X said that AstraDx will use the funds to demonstrate feasibility of its diagnostic ahead of development; the firm aims to develop “a robust, low-cost instrument” to detect neonatal sepsis.
ABL, Siemens Healthineers sign licensing agreement

2 months ago | labpulse.com | Liz Carey

Diagnostics company Advanced Biological Laboratories (ABL) and Siemens Healthineers have signed a licensing and transfer agreement of know-how and intellectual property (IP) rights from Fast Track Diagnostics Luxembourg (FTD) to ABL. FTD, a subsidiary of Siemens Healthineers, was engaged in the development, manufacturing, and sales of IVD and research-use-only molecular testing products.
Study findings presented on early stroke type detection test

2 months ago | labpulse.com | Liz Carey

A new blood test may be able to rapidly distinguish stroke type even before people with stroke symptoms reach the emergency department (ED), according to findings from a preliminary study being presented at the American Stroke Associationâ€™s International Stroke Conference 2025, which is being held February 5-7 in Los Angeles.
U.K. lab leader survey brings 3 key issues to front

2 months ago | labpulse.com | Liz Carey

A survey of over 1,000 laboratory leaders in the U.K. found that concerns regarding staff retention and recruitment are undermining lab innovation and efficiency efforts, according to the firms Synergy and SRG, which published the report. Called Lab Leader Vision 2025, the survey spotlights not only need but demand for automation and workflow optimization in the lab.
Sutter Health, GE HealthCare collaborate on AI-powered imaging services

2 months ago | labpulse.com | Liz Carey

Healthcare system Sutter Health and GE HealthCare have entered into a seven-year strategic partnership to expand and enhance diagnostic imaging services through artificial intelligence (AI) across Sutter Healthâ€™s California network.
BrightHeart presents data on AI-based congenital heart defect screening software

2 months ago | labpulse.com | Liz Carey

BrightHeart presented promising data from two studies on its artificial intelligence (AI)-based software for screening congenital heart defects (CHDs) at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting on January 30 in Aurora, CO. In a statement, Paris-based BrightHeart noted that CHDs are the most common type of birth defect; however, up to 70% of CHD cases go undetected during routine prenatal ultrasounds due to the challenges of screening for them.
What's coming in clinical genomics?

2 months ago | labpulse.com | Liz Carey

The genetics and genomics community is trying to raise awareness of whole genome sequencing (WGS) as a valuable tool in the clinician's diagnostic toolbox, especially for patients with rare and less-common cancers. Five years ago during the throes of the COVID-19 pandemic, there were 187 genomic initiatives globally, of which 50% originated in the U.S. and 19% in Europe, clinical services firm IQVIA reported at the time.
New report outlines conditions for medical device software risk

2 months ago | labpulse.com | Liz Carey

A new document identifies risk characterization related to software as a medical device (SaMD). Developed by the International Medical Device Regulators Forum (IMDRF), the January 29 report introduces a general strategy for characterizing software-specific risks, according to the authors.